CHLORPROMAZINE PAMOATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H16O6.C17H19ClN2S
Molecular Weight	707.234
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCN1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2.OC(=O)C4=CC5=C(C=CC=C5)C(CC6=C7C=CC=CC7=CC(C(O)=O)=C6O)=C4O

InChI

InChIKey=LCKBXWYKBWCAOP-UHFFFAOYSA-N

InChI=1S/C23H16O6.C17H19ClN2S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h1-10,24-25H,11H2,(H,26,27)(H,28,29);3-4,6-9,12H,5,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C17H19ClN2S
Molecular Weight	318.864
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C23H16O6
Molecular Weight	388.3695
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf
Curator's Comment: description was created based on several sources, including http://pubs.acs.org/doi/abs/10.1021/op000018u | https://www.drugs.com/pro/chlorpromazine.html

Chlorpromazine pamoate (also known as chlorpromazine embonate) is a salt of pamoic acid and a chlorpromazine. Pamoate salts are used in pharmaceutical formulations because they show slow dissolution and are useful in formulations where extended duration of action is required. Chlorpromazine is a phenothiazine antipsychotic. It also exerts sedative and antiemetic activity. The precise mechanism whereby the therapeutic effects of chlorpromazine are produced is not known. It has a wide range of activity arising from its depressant actions on the CNS and its alpha-adrenergic blocking and antimuscarinic activities. Chlorpromazine is a dopamine inhibitor; the turnover of dopamine in the brain is also increased. There is some evidence that the antagonism of central dopaminergic function, especially at the D2-dopaminergic receptor, is related to therapeutic effect in psychotic conditions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D1 receptor 101 Target ID: CHEMBL2056 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf	Antagonist 2778	56.0 nM [Ki]
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf	Antagonist 2778	19.0 nM [Kd]
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf	Antagonist 2778	9.0 nM [Kd]
Adrenergic receptor alpha-1 169 Target ID: CHEMBL2094251 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf	Antagonist 2778	2.6 nM [Kd]
Adrenergic receptor alpha-2 113 Target ID: CHEMBL2095158 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf	Antagonist 2778	750.0 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Schizophrenia 298 Sources: http://www.medicatione.com/?c=drug&s=hibernal&ingredient=chlorpromazine%20embonate/chlorpromazine%20hydrochloride	Primary	Not Provided 504	HIBERNAL Approved Use For the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness.
Nausea and vomiting 19 Sources: http://www.medicatione.com/?c=drug&s=hibernal&ingredient=chlorpromazine%20embonate/chlorpromazine%20hydrochloride	Primary	Not Provided 504	HIBERNAL Approved Use For the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness.
Manic-depressive disease 9 Sources: http://www.medicatione.com/?c=drug&s=hibernal&ingredient=chlorpromazine%20embonate/chlorpromazine%20hydrochloride	Primary	Not Provided 504	HIBERNAL Approved Use For the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness.

PubMed

Title	Date	PubMed
Plasma-level studies of chlorpromazine following the administration of chlorpromazine hydrochloride and chlorpromazine embonate in chronic schizophrenics.	1973 Feb	4632509

Patents

Sample Use Guides

In Vivo Use Guide

Acute Schizophrenia/Manic States: usual dose for adults is 500 mg/day. Nausea/Vomiting: usual dose for adults is 10 to 25 mg every 4 to 6 hours as needed. Light Sedation: usual dose for adults is 25 to 50 mg 2 to 3 hours before the operation. Chlorpromazine embonate 144 mg is equivalent to about 100 mg of chlorpromazine hydrochloride.

Route of Administration: Oral

In Vitro Use Guide

The inhibition-dissociation constant (Ki) of a number of neuroleptics for D1 receptors of normal human brain tissue was determined. Phenothiazines ranged from 10 nM to 250 nM, and Ki value for chloropromazine was 56 nM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 22:07:11 GMT 2023` Edited by `admin` on `Fri Dec 15 22:07:11 GMT 2023`
Record UNII	85RG9X8ZHE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLORPROMAZINE PAMOATE

Common Name

English

Chlorpromazine embonate [WHO-DD]

Common Name

English

2-NAPHTHALENECARBOXYLIC ACID, 4,4'-METHYLENEBIS(3-HYDROXY-, COMPD. WITH 2-CHLORO-N,N-DIMETHYL-10H-PHENOTHIAZINE-10-PROPANAMINE (1:1)

Common Name

English

CHLORPROMAZINE EMBONATE [MART.]

Common Name

English

CHLORPROMAZINE EMBONATE

Common Name

English

Code System Code Type Description

SMS_ID

100000088281